Vol. 5 No. 5 (2025)
Reimbursement Reviews

Ravulizumab (Ultomiris)

decorative image of the issue cover

Published May 5, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Ravulizumab (Ultomiris) for IV infusion, 10 mg/mL and 100 mg/mL concentrate for solution for IV infusion.
  • Indication: For the treatment of adult patients with anti–AChR antibody–positive gMG